Loading discussion content. Please wait...
Another major drug fails in clinical trials
Atabecestat has become another Alzheimer's drug that has failed in clinical trials. Following an evaluation of liver safety data from its studies, Johnson and Johnson has decided not to continue development of this drug.
I think that big pharma is now realizing that beta amyloid treatments may not be the answer, and that genetically modified mice are not a good model for Alzheimer's. In my opinion, treating inflammation that increases with age will lead to an effective treatment.
Janssen pulls plug on Alzheimer’s candidate - PharmaTimes http://www.pharmatimes.com/news/janssen_pulls_plug_on_alzheimers_candidate_1235957
Adding to the list of anti-amyloid drug failures for Alzheimer's disease:
Amyloid does no damage to the brain unless it causes oxidation and inflammation and the way it does so is through protein kinase C activation and NMDA receptor activation (memantine is a weak NMDA receptor antagonist).
"Malinow’s team found that when mice are missing the PKC alpha gene, neurons functioned normally, even when amyloid beta was present. Then, when they restored PKC alpha, amyloid beta once again impaired neuronal function. In other words, amyloid beta doesn’t inhibit brain function unless PKC alpha is active."
Limit oxidation and inflammation and you have a chance to treat Alzheimer's disease.